N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy

ACS Medicinal Chemistry Letters

Volumn 2, Issue 6, 2011, Pages 481-484

  Amato, George ^a   Roeloffs, Rosemarie ^a   Rigdon, Greg C ^a   Antonio, Brett ^a   Mersch, Theresa ^a   McNaughton Smith, Grant ^a,c   Wickenden, Alan D ^a,b   Fritch, Paul ^a   Suto, Mark J ^a  

^a Icagen Inc   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c CEAMED   (Spain)

Author keywords

epilepsy; KCNQ2 Q3; Potassium channel

Indexed keywords

BENZAMIDE DERIVATIVE; N (2 CHLOROPYRIMIDIN 5 YL) 3,4 DIFLUOROBENZAMIDE; N (6 CHLOROPYRIDIN 3 YL) 3,4 DIFLUOROBENZAMIDE; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ5; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EPILEPSY; NONHUMAN; PRIORITY JOURNAL; RODENT; STRUCTURE ACTIVITY RELATION;

ANIMALIA; RODENTIA;

EID: 79959253399     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200053x     Document Type: Article

References (21)

1. Brown, D. A.; Adams, P. R. Muscarinic suppression of novel voltage-sensitive K+ current in a vertebrae neuron Nature 1980, 283, 673-676 (Pubitemid 10099998)
2. Wang, H. S.; Pan, Z.; Brown, B. S.; Wymore, R. S.; Cohen, I. S.; Dixon, J. E.; McKinnon, D. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel Science 1998, 282, 1890-1893 (Pubitemid 28555268)
3. Biervert, C.; Schroeder, B. C.; Kubisch, C.; Berkovic, S. F.; Propping, P.; Jentasch, T. J.; Steinlein., O. K. A potassium channel mutation in neonatal human epilepsy Science 1998, 279, 403-406 (Pubitemid 28063379)
4. Charlier, C.; Singh, N. A.; Ryan, S. G.; Lewis, T. B.; Reus, B. E.; Leach, R. J.; Leppert, M. A pore mutation in the novel KQT-like potassium channel gene in an idiopathic epilepsy family Nat. Genet. 1998, 18, 53-55 (Pubitemid 28027879)
5. Sing, N. A.; Chalier, C.; Stauffer, D.; DuPont, B. R.; Leach, R. J.; Melsi, R.; Ronen, G. M.; Bjerre, I.; Quattlebaum, T.; Murphy, J.V. A novel potassium channel gene, KCNQ2 is mutated in inherited epilepsy of newborns Nat. Genet. 1998, 18, 25-29 (Pubitemid 28027874)
6. Lerche, H.; Biervert, C.; Alekov, A. K.; Schleithoff, L.; Lindner, M.; Klinger, W.; Bretschneider, F.; Mitrovic, N.; Jurkat-Rott, K.; Bode, H. A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions Ann. Neurol. 1999, 46, 305-312 (Pubitemid 29416267)
7. Watanabe, H.; Nagata, E.; Kosaki, A.; Nakurmura, M.; Yokoyama, M; Tanaka, K.; Sasai, H. Disruption of epilepsy KCNQ2 gene results in neural hyperexcitability J. Neurochem. 2000, 75, 28-33 (Pubitemid 30418165)
8. Yang, Y.; Beyeer, B. J.; Otto, J. F.; O'Brien, T. P.; Letss, V. A.; White, H. S.; Frankel, W. N. Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold Mol. Genet. 2003, 12, 975-984 (Pubitemid 36553517)
9. Peters, H. C.; Pongs, O.; Storm, J. F.; Isbrandt, D. Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior Nat. Neurosci. 2005, 8, 51-60 (Pubitemid 41236731)
10. Wickenden, A. D.; Roeloffs, R.; McNaughton-Smith, G.; Rigdon, G. C. KCNQ potassium channels: Drug targets for the treatment of epilepsy and pain Expert Opin. Ther. Targets 2004, 14, 457-469 (Pubitemid 38489491)
11. McNaughton-Smith, G.; Wickenden, A. D. Compounds that activate KCNQ(2-5) family of potassium ion channels. In Voltage-Gated Ion Channels as Drug Targets; Triggle, D., Ed.; Wiley-VCH: Weinheim, 2006; Chapter 7.6, pp 355 - 380.
12. Munro, G.; Dalby-Brown, W. Kv7 (KCNQ) channel modulators and neuropathic pain J. Med. Chem. 2007, 50, 2576-2582 (Pubitemid 46896062)
13. Gribkoff, V. K. The therapeutic potential of neuronal Kv7 (KCNQ) channel modulators: An update Expert Opin. Ther. Targets 2008, 12, 565-581 (Pubitemid 351699476)
14. Jespersen, T.; Grunnet, M.; Olesen, S. P. The KCNQ1 potassium channel: From gene to physiological function Physiology (Bethesda) 2005, 20, 408-416 (Pubitemid 41812424)
15. The following references demonstrate the presence of a conserved tryptophan in KCNQ2-5 that is not present in KCNQ1 and may account for the agonist activity seen vs KCNQ1 block. Lange, W.; Geissendrfer, J.; Schenzer, A.; Grotzinger, J.; Seebohm, G.; Friedrich, T.; Schwake, M. Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels Mol. Pharmacol. 2009, 75, 272-280
16. Padilla, K.; Wickenden, A. D.; Gerlach, A. C.; McKormack, C. The KCNQ2/Q3 selective channel opner ICA-27243 binds to a novel voltage-sensor domain site Neurosci. Lett. 2009, 465, 138-142
17. Activating KCNQ3/Q5 channels may produce vascular side effects: Ng, F. L.; Davis, A. J.; Jepps, T. A.; Harhun, M. I.; Yeung, S. Y.; Wan, A.; Reddy, M.; Melville, D.; Nardi, A.; Khong, T. K.; Greenwood, I. A. Expression and function of the K+ channel KCNQ genes in human arteries Br. J. Pharmacol. 2011, 162, 42-53
18. 50 values >10 μM.
19. Roeloffs, R.; Wickenden, A. D.; Crean, C.; Werness, S.; McNaughton-Smith, G.; Staples, J.; McNamara, J. O.; Ghodadra, N.; Rigdon, G. C. In vivo profile of ICA-27243, a potent and selective KCNQ2/Q3 activator in rodent anticonvulsant models J. Pharmacol. Exp. Ther. 2008, 326 (3) 818-828
20. Wickenden, A.; Krajewski, J.; London, B.; Wagoner, P. K.; Wilson, W. A.; Clark, S.; Roeloffs, R.; McNaughton-Smith, G.; Rigdon, G. C. ICA-27243: A novel, selective KCNQ2/Q3 potassium channel activator Mol. Pharmacol. 2008, 73, 977-986
21. A 14 day toxicity study conducted was conducted in rats dosed orally with compound 12 or the metabolite 2-chloro-5-aminopyridine. Nonhemolytic anemia was observed after dosing with both compounds.